Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma

Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma

IntroductionThe programmed death-1 (PD-1) immune checkpoint inhibitor pembrolizumab is currently approved in the US for the first-line (1L) treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), either alone or in combination with platinum and 5-fluorouracil (5-FU)....

Full description

Bibliographic Details
Main Authors: Christopher M. Black, Dandan Zheng, Gleicy M. Hair, Lei Ai, Liya Wang, Daisuke Goto, Nati Lerman, Behzad Bidadi, Glenn J. Hanna
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Oncology
Subjects:
head and neck squamous cell carcinoma
antineoplastic agents
PD-1
taxanes
Kaplan-Meier estimate
patient outcomes
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1348045/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1348045/full

Similar Items